Sygnature Discovery

Wishing everyone a Happy Diwali! This Festival of Lights celebrates the triumph of light over darkness, good over evil, and knowledge over ignorance. May this joyful occasion bring warmth, health, and happiness to you and your families. Best wishes, From all the team at Sygnature Discovery

📢 REMINDER: ONE WEEK LEFT TO DOWNLOAD FOR FREE! 🌟 Discover how we are Defining Directions in Targeted Protein Degradation (#TPD) 🌟 💥We’re proud to share our latest book chapter, recently published in "Progress in Medicinal Chemistry" Vol. 63 (Elsevier), authored entirely by Sygnature Discovery scientists. 🙌 Kudos to Allan Jordan, Roland Hjerpe, Diana Castagna, Benoit Gourdet, Philip MacFaul, Andrew Novak, Etienne Rochette & Guillaume Revol who were recently invited to collate our thoughts and opinions on the latest advances in the heterobifunctional therapeutics space.🙌 Get exclusive insights on shaping the future of TPD, download it for #free until Nov. 8th! 👉 Download here: https://lnkd.in/em6hFXMA #DefiningDirections #TargetedProteinDegradation #ScientificInnovation #CRO

💥 Struggling with the #scale-up, #formulation and #purity of heterobifunctional #degraders? Download this #TPD masterpiece, authored exclusively by Sygnature Discovery scientists. #Free until Nov. 8th! 👉 https://lnkd.in/em6hFXMA 🙌 Kudos to Allan Jordan, Roland Hjerpe, Diana Castagna, Benoit Gourdet, Philip MacFaul, Andrew Novak, Etienne Rochette & Guillaume Revol for their contributions in the recently published "Progress in Medicinal Chemistry", Volume 63, Elsevier. #MedChem #DefiningDirections #Innovation #TargetedProteinDegradation #ScientificInnovation #CRO

💥 Curious about #DMPK strategies for #degraders? Download this #TPD masterpiece, authored exclusively by Sygnature Discovery scientists. #Free until Nov. 8th! 👉 https://lnkd.in/em6hFXMA 🙌 Kudos to Allan Jordan, Roland Hjerpe, Diana Castagna, Benoit Gourdet, Philip MacFaul, Andrew Novak, Etienne Rochette & Guillaume Revol for their contributions in the recently published "Progress in Medicinal Chemistry", Volume 63, Elsevier. #MedChem #DefiningDirections #Innovation #TargetedProteinDegradation #ScientificInnovation #CRO

Sygnature Discovery is delighted to get #fundraising efforts underway here on LinkedIn on behalf of our CEO, Simon Hirst, as he takes part once again in the CEO Sleepout at Meadow Lane football stadium in #Nottingham on November 7! CEO Sleepout is a national #charity set up to inspire the business community to unite to fight homelessness; raising money for frontline services, helping to change lives. The charity is joining forces with The Friary, Emmanuel House Support Centre and Notts County Foundation to make this change a reality. The aim of the event is for 40 big-hearted business people to raise a massive £40,000 by sleeping outdoors for the night. This will boost local charities in their bid to prevent homelessness in the local area - just when it's needed most. A night sleeping outdoors may not be warm or comfortable, but it could change somebody's life. Click here to visit Simon’s personal fundraising page and make a donation: https://lnkd.in/ejuxZeTB We wish Simon all the best in his efforts to smash his fundraising targets for a charity that remains close to his heart, and we look forward to sharing his results shortly after the event. #ceosleepout #charityevent

A well-executed hit-finding strategy is one of the cornerstones of successful drug development. High-quality, structurally diverse hits provide a strong foundation to progress your compound to clinical candidate. 🔵 What if you could leverage multiple screening technologies all within one powerful, integrated platform to produce well-characterized hits, tailored to today’s most challenging new targets? HIT SYNERGY is a powerful hit ID platform from Sygnature Discovery which combines cutting-edge affinity screening, fragment-based drug discovery, high throughput screening and virtual screening with a carefully designed strategy to meet your project requirements around budgets, timelines and goals. Set your project up for success. Learn more about HIT SYNERGY from Sygnature Discovery, here 👇 https://lnkd.in/gNsRrR36 #drugdiscovery #pharma #biotech

💥 Curious about drug discovery #biology for #degraders? Download this #TPD masterpiece, authored exclusively by Sygnature Discovery scientists. #Free until Nov. 8th! 👉 https://lnkd.in/em6hFXMA 🙌 Kudos to Allan Jordan, Roland Hjerpe, Diana Castagna, Benoit Gourdet, Philip MacFaul, Andrew Novak, Etienne Rochette & Guillaume Revol for their contributions in the recently published "Progress in Medicinal Chemistry", Volume 63, Elsevier. #MedChem #DefiningDirections #Innovation #TargetedProteinDegradation #ScientificInnovation #CRO

💥 Interested in medicinal #chemistry approaches for #degraders? Download this #TPD masterpiece, authored exclusively by Sygnature Discovery scientists. #Free until Nov. 8th! 👉 https://lnkd.in/em6hFXMA 🙌 Kudos to Allan Jordan, Roland Hjerpe, Diana Castagna, Benoit Gourdet, Philip MacFaul, Andrew Novak, Etienne Rochette & Guillaume Revol for their contributions in the recently published "Progress in Medicinal Chemistry", Volume 63, Elsevier. #MedChem #DefiningDirections #Innovation #TargetedProteinDegradation #ScientificInnovation #CRO

🌟 Discover how we are Defining Directions in Targeted Protein Degradation (#TPD) 🌟 💥We’re proud to share our latest book chapter, just published in "Progress in Medicinal Chemistry" Vol. 63 (Elsevier), authored entirely by Sygnature Discovery scientists. 🙌 Kudos to Allan Jordan, Roland Hjerpe, Diana Castagna, Benoit Gourdet, Philip MacFaul, Andrew Novak, Etienne Rochette & Guillaume Revol who were recently invited to collate our thoughts and opinions on the latest advances in the heterobifunctional therapeutics space.🙌 Get exclusive insights on shaping the future of TPD, download it for #free until Nov. 8th! 👉 Download here: https://lnkd.in/em6hFXMA #DefiningDirections #TargetedProteinDegradation #ScientificInnovation #CRO

Radiotherapy Enhances the Efficacy of the PARP Inhibitor Niraparib in a Preclinical Model of Triple-Negative Breast Cancer...   Radiotherapy is a key treatment for various cancers often in combination with other therapies. Our recent research has demonstrated the utility and value of our preclinical radiotherapy platform for testing the efficacy of novel therapeutic agents in combination with this clinically relevant standard of care in drug discovery research. The data shows that radiotherapy enhances efficacy and modulates pathway relevant tumour biomarkers of the PARP inhibitor niraparib in a preclinical model of triple-negative breast cancer.   ⭕ At the EORTC-NCI-AACR Symposium in Barcelona, Friday October 25th, Pablo Binder will present our latest work on this therapeutic combination.   ⭕ Don’t miss this chance to discuss our capabilities at poster PB320. Our Business Development Director, Katie Headland, will also be attending and is available to discuss how we can support your project needs!   Can't make the event? Download the poster for more insights👇 https://lnkd.in/eRJNfEm6